Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: The transgene determines the composition of the inflammatory infiltrate

Melanoma Research

Volumn 18, Issue 2, 2008, Pages 104-111

  Hofbauer, Günther F L ^a   Baur, Tobias ^a   Bonnet, Marie Claude ^b   Tartour, Eric ^c   Burg, Günter ^a   Berinstein, Neil L ^d   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SANOFI PASTEUR   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Sanofi Pasteur   (Canada)

Author keywords

ALVAC; Granulocyte macrophage colony stimulating factor; Immunotherapy; Interleukin 2; Melanoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; VIRUS VECTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANARYPOX VIRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPIGMENTATION; DOSE RESPONSE; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; INJECTION SITE REACTION; LEIOMYOSARCOMA; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN METASTASIS; SWELLING; T LYMPHOCYTE; TRANSGENE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEIOMYOSARCOMA; MACROPHAGES; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES; VIRAL VACCINES;

EID: 40849126694     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f702cf     Document Type: Article

References (33)

1. Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol 2004; 22:251-265.
2. Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61:1071-1074.
3. Fierlbeck G, d'Hoedt B, Stroebel W, Stutte H, Bogenschutz O, Rassner G. Intralesional therapy for metastatic melanoma with recombinant interferon-beta [in German]. Hautarzt 1992; 43:16-21.
4. Vaquerano JE, Cadbury P, Treseler P, Sagebiel R, Leong SP. Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol 1999; 135:1276-1277.
5. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16:35-48.
6. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89:1620-1626.
7. Dummer R, Bergh J, Karlsson Y, Horowitz JA, Mulder NH, Huinink DTB, et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000; 7:1069-1076.
8. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6:350-363.
9. Perkus ME, Panicali D, Mercer S, Paoletti E. Insertion and deletion mutants of vaccinia virus. Virology 1986; 152:285-297.
10. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93:11341-11348.
11. Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 2001; 19:2571-2575.
12. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-3543.
13. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22:3188-3192.
14. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915.
15. Council for International Organizations of Medical Sciences. Reporting adverse drug reactions: definitions of terms and criteria for their use. Geneva: Council for International Organizations of Medical Sciences; 1999.
16. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998; 8:337-343.
17. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998; 25:204-209.
18. Hofbauer GF, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle FO, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151:1549-1553.
19. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357.
20. Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 2001; 50:373-381.
21. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-3350.
22. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9:289-295.
23. Tartour E, Mehtali M, Sastre-Garau X, Joyeux I, Mathiot C, Pleau JM, et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 2000; 83:1454-1461.
24. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, et al. Phase I clinical trial of a recombinant canarypox virus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49:504-514.
25. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17:332-337.
26. Ullenhag GJ, Frodin JE, Mosolits S, Kiaii S, Hassan M, Bonnet MC, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 2003; 9:2447-2456.
27. Van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T Cells. J Clin Oncol 2005; 23:9008-9021.
28. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005; 11:4168-4175.
29. Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, et al. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 2005; 16:91-100.
30. Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 2006; 106:890-899.
31. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 2003; 171:4893-4897.
32. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171:4898-4904.
33. Von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7:1181-1191.